Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
EU backs approval of Alexza's agitation drug Adasuve
Alexza Pharmaceuticals' investigational drug Adasuve was recommended for approval by a European Medicines Agency committee for use in controlling agitation in patients with bipolar disorders and schizophrenia. The drug, which also is being evaluated by the FDA, was recommended for use in hospitals with the supervision of a health care provider.
Reuters (12/14)

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .